Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 22, 2021 08:15 ET | Source: Pluristem Therapeutics, Inc.

Pluristem CEO Issues Shareholder Update

HAIFA, Israel, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq: PSTI) (TASE: PSTI), a leading biotechnology company, today issued an update to its shareholders from its Chief...
July 19, 2021 07:00 ET | Source: Pluristem Therapeutics, Inc.

Pluristem Appoints Prof. Varda Shalev MD and Mr. Doron Birger to Join its Board of Directors

HAIFA, Israel, July 19, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq: PSTI) (TASE: PSTI), a leading biotechnology company, today announced the Board of Director appointments of Prof....
July 08, 2021 07:10 ET | Source: Pluristem Therapeutics, Inc.

Pluristem Brings ARDS Associated with COVID-19 Phase II Studies to Clinical Readout

The company will analyze data based on patients enrolled to date in COVID-19 Phase II studies in U.S., Europe and IsraelTopline results are expected during the fourth quarter of 2021 HAIFA, Israel,...
May 25, 2021 07:00 ET | Source: Pluristem Therapeutics, Inc.

Pluristem to Receive €20M Non-Dilutive Funding from the European Investment Bank

HAIFA, Israel, May 25, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI) (the “Company”), a leading biotechnology company, today announced the receipt of a “Disbursement...
April 29, 2021 07:00 ET | Source: Pluristem Therapeutics, Inc.

Pluristem reports positive topline Phase I results in innovative hematology program, which is first to study PLX-R18 in humans

New therapy has potential to generate improved blood counts in all three blood cell lineages, a meaningful advantage over existing treatmentsThe company will conduct an analyst and investor call on...
February 02, 2021 08:30 ET | Source: Pluristem Therapeutics, Inc.

Pluristem Therapeutics Inc. Announces $30 Million Registered Direct Offering

HAIFA, Israel, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic...
January 27, 2021 07:00 ET | Source: Pluristem Therapeutics, Inc.

Pluristem Announces Uplisting to the Nasdaq Global Market®

HAIFA, Israel, Jan. 27, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic...
January 06, 2021 07:00 ET | Source: Pluristem Therapeutics, Inc.

Pluristem Announces Appointments of Two Directors to Board

HAIFA, Israel, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic...
December 29, 2020 07:00 ET | Source: Pluristem Therapeutics, Inc.

Pluristem Enters Collaboration With Pharmaceutical Company Innovare R&D to Expand Pluristem’s ARDS Associated With COVID-19 Program to Mexico

HAIFA, Israel, Dec. 29, 2020 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic...
December 09, 2020 04:00 ET | Source: Pluristem Therapeutics, Inc.

Pluristem Announces DMC Recommendation Following Interim Analysis of its Phase III CLI Study

The CLI study is unlikely to meet its primary endpoint by the time of the final analysis Substantial low number of events in the placebo group in the CLI study decreased the statistical power of the...